

Figure S1. EphA8 overexpression increases proliferation and motility in HS-578T breast cancer cells. Effect of EphA8 overexpression alone or in combination with paclitaxel treatment on HS-578T cell (A) proliferation, analyzed by Cell Counting Kit-8 assay; (B) apoptosis, analyzed by Annexin V-FITC and PI staining followed by flow cytometry; (C) invasion, analyzed via Transwell invasion assay (magnification, x200) and (D) motility, assessed by wound healing assay (magnification, x40). Data are presented as the mean  $\pm$  SD (n=3). \*P<0.05, \*\*P<0.01. EphA8, erythropoietin-producing hepatocellular receptor A8; NC, negative control; OD, optical density.




Table SI. Sequences of shRNA for erythropoietin-producing hepatocellular receptor A8.

shRNA	Sequence (5'→3')
shRNA-1	TTCTGGATCGAGGCCGTCAAT
shRNA-2	TCTATGCTGAGATCAAGTTTA
shRNA-3	GGAGAAGATGCACTATCAGAA
shRNA-4	ACCAGGTTTGCAACGTCATGA
shRNA-NC	TTCTCCGAACGTGTCACGT
sh, short hairpin; NC, negative control.	

Table SII. Association between expression levels of EphA8 and clinicopathological characteristics in patients with breast cancer.

Characteristic	EphA8 expression, %			$\chi^2$	P-value
	n	Low	High		
Total	151	104	47		
Age at diagnosis, years				0.087	0.768
≤Median	83	58	25		
>Median	68	46	22		
NHG				0.550	0.759
I	30	20	10		
II	71	51	20		
III	50	33	17		
Tumor size, mm				16.729	<0.001 <sup>a</sup>
≤20	66	57	9		
>20	85	47	38		
Nodal status				3.635	0.056
Negative	94	70	24		
Positive	57	34	23		
TNM stage				13.160	<0.001 <sup>a</sup>
0/I/II	115	88	27		
III/IV	36	16	20		
ER status				1.500	0.221
Negative	66	42	24		
Positive	85	62	23		
PR status				0.399	0.528
Negative	94	63	31		
Positive	57	41	16		
Ki-67 status				2.917	0.088
<14%	83	62	21		
≥14%	68	42	26		

ER/PR expression >10% was considered to be positive.  $\chi^2$  was used to test the significance between groups. <sup>a</sup>P<0.05. EphA8, erythropoietin-producing hepatocellular receptor A8; ER, estrogen receptor; PR, progesterone receptor; NHG, Nottingham histological grade.